BR112021025645A2 - Degradação de proteína alvo de parp14 para uso em terapia - Google Patents

Degradação de proteína alvo de parp14 para uso em terapia

Info

Publication number
BR112021025645A2
BR112021025645A2 BR112021025645A BR112021025645A BR112021025645A2 BR 112021025645 A2 BR112021025645 A2 BR 112021025645A2 BR 112021025645 A BR112021025645 A BR 112021025645A BR 112021025645 A BR112021025645 A BR 112021025645A BR 112021025645 A2 BR112021025645 A2 BR 112021025645A2
Authority
BR
Brazil
Prior art keywords
parp14
therapy
target protein
protein degradation
quinazolinones
Prior art date
Application number
BR112021025645A
Other languages
English (en)
Portuguese (pt)
Inventor
Kalai Swinger Kerren
Wayne Kuntz Kevin
B Schenkel Laurie
Marie Vasbinder Melissa
J N Wigle Timothy
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of BR112021025645A2 publication Critical patent/BR112021025645A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112021025645A 2019-06-19 2020-06-18 Degradação de proteína alvo de parp14 para uso em terapia BR112021025645A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19
PCT/US2020/038377 WO2020257416A1 (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Publications (1)

Publication Number Publication Date
BR112021025645A2 true BR112021025645A2 (pt) 2022-02-01

Family

ID=71527971

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025645A BR112021025645A2 (pt) 2019-06-19 2020-06-18 Degradação de proteína alvo de parp14 para uso em terapia

Country Status (11)

Country Link
US (2) US20220388985A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986887A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537349A (cg-RX-API-DMAC7.html)
KR (1) KR102993656B1 (cg-RX-API-DMAC7.html)
CN (2) CN114206853A (cg-RX-API-DMAC7.html)
AU (1) AU2020296063B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025645A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142002A1 (cg-RX-API-DMAC7.html)
MA (1) MA56513A (cg-RX-API-DMAC7.html)
SG (1) SG11202112980TA (cg-RX-API-DMAC7.html)
WO (1) WO2020257416A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14
WO2022150667A1 (en) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
JP2024505228A (ja) * 2021-01-29 2024-02-05 ライボン・セラピューティクス・インコーポレイテッド 炎症性疾患を処置する方法
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224B (zh) * 2022-06-07 2026-05-08 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
CN119923391A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
CN119923394A (zh) * 2022-07-29 2025-05-02 艾伯维新加坡运营私人有限公司 在疗法中使用的parp14的靶向蛋白降解
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024251205A1 (zh) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 一种喹唑啉酮衍生物及其在医药上的应用
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
EP4119552A1 (en) * 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US20210154184A1 (en) * 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14

Also Published As

Publication number Publication date
CN114206853A (zh) 2022-03-18
JP2025102917A (ja) 2025-07-08
EP3986887A1 (en) 2022-04-27
SG11202112980TA (en) 2021-12-30
WO2020257416A1 (en) 2020-12-24
JP7844707B2 (ja) 2026-04-13
CN120398840A (zh) 2025-08-01
KR20220024098A (ko) 2022-03-03
CA3142002A1 (en) 2020-12-24
JP2022537349A (ja) 2022-08-25
AU2020296063A1 (en) 2021-12-23
AU2020296063B2 (en) 2026-01-29
MA56513A (fr) 2022-04-27
US20260125362A1 (en) 2026-05-07
KR102993656B1 (ko) 2026-07-23
US20220388985A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112021024236A2 (pt) Proteínas multiespecíficas
BR112022003956A2 (pt) Anticorpos anti-cd73
MX2023002507A (es) Inhibidores de cd73.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2022005256A (es) Inhibidores de cd73.
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
EP4349997A3 (en) Anti-garp antibody
EA201792348A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
MX392789B (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias
EA201792509A1 (ru) Лечение рака
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112021019703A2 (pt) Compostos heterocíclicos e usos dos mesmos
BR112022012283A2 (pt) Combinações
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
MX2022002337A (es) Polipéptidos de tff2 modificados.
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
UY37449A (es) Anticuerpos anti-chikv y usos de éstos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]